Clinical trials

#Biologics / Biotechnology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Preclinical #Regulatory #Sequencing #System biology #Systems biology #Theranostics #Therapeutics

Fewer drugs approved, more money spent – Where’s the beef?

Fewer drugs approved, more money spent - Where's the beef? By G. Steven Burrill Three years ago, when biotech was at its Wall Street heights, personalised medicine and its promise were on everyone's lips. Billions of dollars were being put to work to make targeted medicine a reality... and genomics… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Organic chemistry #Protein chemistry / Proteomics #RNA #Screening #Sequencing #System biology #Systems biology

Recent advances in mass spectrometry for drug discovery and development

Recent advances in mass spectrometry for drug discovery and development By Dr Nelson Cooke Of the numerous types of analytical techniques used in drug discovery and development, mass spectrometry (MS) has become one of the most powerful tools for the analyses of a wide range of chemical and biological entities. Read More

#Archive

#Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #Oncology #Pathology #Preclinical #RNA #Stem cells #System biology #Systems biology #Toxicology

DNA repair inhibition to treat cancer and other serious illnesses

DNA repair inhibition to treat cancer and other serious illnesses By Professor Stephen P. Jackson and Cheryl L. Bishop The stability of an organism's genome is essential for healthy functioning and survival. The information content and integrity of the genome are so important that a range of maintenance and repair… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Automation / robotics #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Lead discovery #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Target validation #Therapeutics

Urinary troubles for more than the ageing

Urinary troubles for more than the ageing By Dr Anthony PDW Ford The needs of younger incontinence sufferers coupled with the ageing of the baby-boomer population portend a big boost in demand for effective and well tolerated new medicines for lower urinary-tract dysfunction. This market is under-served today, presenting a… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Protein BIOMARKER Strategies

By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease state or a drug… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Biomarkers #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Lead discovery #Orphan drugs #Regulatory #RNA #Screening

Biotechnology-based Orphan Drugs – Achievements and challenges

Biotechnology-based Orphan Drugs - Achievements and challenges By Dr Erik Tambuyzer For many patients suffering from rare diseases, there are simply no medicines available to treat their condition. With an estimated 20-30 million such patients in Europe alone, rare diseases collectively represent a significant unmet medical need. Individual disease groups,… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Protein chemistry / Proteomics #Screening #Sequencing #System biology #Systems biology #Therapeutics

The cost and value of three-dimensional protein structure

The cost and value of three-dimensional protein structure By Professor Raymond C. Stevens During the past few years we have seen the cost of protein three-dimensional structure determination begin to converge by protein family type, there has been a commoditisation of high-throughput structure based drug discovery technology components, and the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #Metabolomics #Molecular medicine #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Molecular pathology and the art of drug design

Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #Immunology #Immunology / Virology & Vaccines #Oncology #PCR #Protein chemistry / Proteomics #Regulatory #RNA

Public Relations and the Drug Discovery Industry

Public Relations and the Drug Discovery Industry By Dr Richard Franklin The use of the Public Relations (PR) industry to promote all facets of the pharmaceutical industry is on the increase. We take a brief look at the various uses of PR and the sectors that are being promoted. Public… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Mass spectrometry / NMR #Oncology #PCR #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The Protein Biochip Content Problem

The Protein Biochip Content Problem By Dr Steven Bodovitz The protein biochip industry has a content problem that is not only slowing its development as a whole but possibly the development of the entire proteomics industry. In science, for a problem to have its own name, it needs to be… Read More

#Archive

#Academic #Analysis #Animal models #Cell / tissue culture #Cell culture #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Pharmokinetics #RNA #Stem cells #System biology #Systems biology

New developments in antigen-specific immunotherapies

New developments in antigen-specific immunotherapies By Dr Jorg Schneider and Professor Andrew J. McMichael Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer. Vaccination has been used effectively for more than 200 years to protect individuals from a range of infectious diseases such as polio… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Immunology #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Organic chemistry #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Functional proteomics in drug discovery

Functional proteomics in drug discovery By Dr Stefan W. Henning and Dr Leodevico L. Ilag The critical bottleneck of the drug discovery process is developing the right drug for the right target. Today proteins represent more than 90% of druggable targets and will most likely remain the single most important… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #RNA #Screening

In Silico Structure-based Drug Design – Shifting the bottleneck?

In Silico Structure-based Drug Design - Shifting the bottleneck? By Dr Jonathan Heal Drug Discovery The use of in silico methods in drug design has grown significantly in popularity over the past couple of years. Indeed many pharma companies have already adopted some type of virtual screening capability to complement… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #PCR #Pharmokinetics #RNA #Screening

Surface Plasmon Resonance’s impact on drug discovery – resolution, throughput and versatility

Surface Plasmon Resonance's impact on drug discovery - resolution, throughput and versatility By Dr David G. Myszka and Dr Rebecca L. Rich Surface plasmon resonance (SPR) biosensors have rapidly become a standard tool within the pharmaceutical and biotechnology industries. Label-free, real-time measurements are the calling card for this technology, which… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Pathology #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Target validation #Therapeutics

The role of ZEBRAFISH in drug discovery

The role of ZEBRAFISH in drug discovery By Dr Paul Goldsmith and Roberto Solari The NIH has ranked the Zebrafish as the third most important experimental organism after man, the Sanger Centre is sequencing the genome and many medical researchers are shifting over to it. But will the zebrafish have… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #PCR #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Target validation

TRANSCRIPTOMICS – Realising the promise with a new era of drug discovery and diagnostics

TRANSCRIPTOMICS - Realising the promise with a new era of drug discovery and diagnostics By Dr Bruce Seligmann The advent of modern genomics has provided new ways to link targets to diseases and validate these targets. The result is the potential for a new era of drug discovery transcriptomics or… Read More

#Archive